Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

Jeffery M. Vance, Lindsay A. Farrer, Yadong Huang, Carlos Cruchaga, Bradley T. Hyman, Margaret A. Pericak-Vance, Alison M. Goate, Michael D. Greicius, Anthony J. Griswold, Jonathan L. Haines, Julia Tcw, Gerard D. Schellenberg, Li Huei Tsai, Joachim Herz, David M. Holtzman

Research output: Contribution to journalReview articlepeer-review

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024.

Original languageEnglish
JournalAnnals of neurology
DOIs
StateAccepted/In press - 2024

Fingerprint

Dive into the research topics of 'Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this